The Dutasteride Serum DHT Data: 90%-Plus Suppression Quantified
Affiliate disclosure: This page contains sponsored links. We earn commissions at no extra cost to you. Clinical content is editorially independent.
Dutasteride at 0.5mg reduces serum DHT by approximately 90–95% versus finasteride's 65–70%. The difference in suppression depth is real and produces demonstrably better hair density outcomes — at the cost of deeper androgen system effects.
The distinction between finasteride and dutasteride for AGA treatment is pharmacologically specific: the difference in 5-AR isoform coverage produces measurably different degrees of DHT suppression, which translates to measurably different clinical hair outcomes. Understanding the pharmacokinetics of each drug informs both the treatment choice and the management of side effects and discontinuation.
The two 5-AR isoforms
5-Alpha-reductase exists as three isoforms in humans. Type 2 (expressed primarily in the prostate, liver, and skin) is the primary isoform responsible for DHT production in the scalp follicle dermal papilla. Finasteride selectively inhibits type 2. Type 1 (expressed in sebaceous glands, liver, and some brain regions) contributes approximately 30% of systemic DHT production. Dutasteride inhibits both type 1 and type 2.
Suppression depth in clinical pharmacokinetics
Clark et al. (2004) quantified serum DHT suppression by dutasteride at various doses. At the 0.5mg clinical dose, serum DHT was suppressed by approximately 90–95% at steady state (achieved after approximately one to three months of daily dosing). The residual serum DHT reflects DHT from sources independent of 5-AR (primarily adrenal DHEA conversion) that dutasteride cannot suppress.
Finasteride at 1mg produces approximately 65–70% serum DHT suppression — with the residual reflecting both unblocked type 1 activity and the pharmacological ceiling of type 2 inhibition. The difference is not trivial: 10% residual DHT (dutasteride) versus 30–35% residual DHT (finasteride) represents a substantial additional reduction in the DHT signal reaching follicle androgen receptors.
Hair efficacy difference
Olsen et al. (2006) directly compared dutasteride 0.5mg and 2.5mg versus finasteride 5mg in AGA. Both dutasteride doses showed significantly greater hair count increase at 24 weeks than finasteride 5mg. This superiority in efficacy is consistent with the deeper DHT suppression and dual isoform coverage. Other head-to-head studies and meta-analyses consistently show dutasteride outperforming finasteride on hair density endpoints.
Clinical Q&A
How does dutasteride compare to finasteride for DHT suppression?
Finasteride (1mg) inhibits 5-alpha-reductase type 2 and reduces serum DHT by approximately 65–70%. Dutasteride (0.5mg) inhibits both type 1 and type 2 5-AR and reduces serum DHT by approximately 90–95%. The additional 20–25 percentage points of suppression translate to measurably better hair density outcomes in head-to-head comparisons.
Is dutasteride FDA-approved for hair loss?
Not specifically for AGA in the US. It is FDA-approved for benign prostatic hyperplasia (BPH). Off-label use for AGA is widespread in clinical practice, and it has received regulatory approval for AGA specifically in some other markets (notably Japan and South Korea). The off-label use is supported by a substantial clinical evidence base.
Are dutasteride's side effects worse than finasteride's?
Due to deeper DHT suppression and dual enzyme inhibition, dutasteride has longer duration of effect and more complete androgenic suppression than finasteride. The side effect profile (libido, sexual function, mood) is broadly similar but the depth and duration of effects differ. The very long half-life (~5 weeks) means that discontinuation does not rapidly clear the drug, unlike finasteride.
References & further reading
- Clark RV, et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. Journal of Clinical Endocrinology and Metabolism, 2004.
- Olsen EA, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. Journal of the American Academy of Dermatology, 2006.
Get a clinical evaluation
Care Bare Rx
Online consultation with licensed prescribers for hair loss evaluation. Compounded finasteride, minoxidil, and combination formulas prescribed and shipped after a clinical intake review.
Start Your Care Bare Rx Intake Paid linkSesame Care
Direct-booking platform for licensed physician consultations. FDA-approved brand-name and generic hair loss prescriptions at transparent prices, no insurance or membership required.
Browse Sesame Care Providers Paid linkStrut Health
Telehealth platform offering prescription hair loss formulations after licensed-provider review of an online intake. Topical and oral options available.
Strut Health received FDA Warning Letter #721448 (February 2026) regarding misbranding of compounded medications. We disclose this on every Strut appearance and exclude Strut from featured rankings. Weigh this when comparing options.
RxSpan MD
Online medical consultations with licensed prescribers across hair loss and other treatment categories. Direct-to-door fulfilment.
Explore RxSpan MD Paid linkCompounded medications: These preparations are made by a pharmacy for an individual patient and are not FDA-approved for safety, effectiveness, or manufacturing quality. Discuss trade-offs with a licensed prescriber.
Affiliate Disclosure: This site earns commissions on referrals at no extra cost to you. Clinical content is independent.
Medical disclaimer: This article is educational and does not constitute clinical advice, diagnosis, or treatment recommendations. Consult a licensed physician or dermatologist before starting, stopping, or changing any medication or treatment for hair loss.